EDGEWISE THERAPEUTICS INC (EWTX)
US28036F1057 - Common Stock
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Why Edgewise Therapeutics Stock Is Up 50% on Thursday
One of the biopharma company's heart drugs performs as well as initially hoped.
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics.
Notable Friday Option Activity: IBKR, EWTX, SLQT
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q2 2024
EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Edgewise Therapeutics (NASDAQ:EWTX) just reported results for the second quarte...
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
7 Small-Cap Stocks to Buy for Large-Scale Gains
Although small-cap stocks are incredibly risky, their underappreciated nature potentially gives them a high performance ceiling.
Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs
What sectors outperformed after Trump won the 2016 election, and which outperformed during his term?
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day
The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM.
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024
EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
Commit To Buy Edgewise Therapeutics At $12.50, Earn 22.1% Annualized Using Options
Commit To Purchase Edgewise Therapeutics At $12.50, Earn 19.2% Annualized Using Options
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
Edgewise Therapeutics Non-GAAP EPS of $0.47 (NASDAQ:EWTX)
Edgewise Therapeutics, a pharmaceutical company, reports Q4 Non-GAAP EPS of $0.47 and holds cash reserves of $318.4 million as of December 31, 2023.
